C
Asymmetric dimethylarginine
Novel & Emerging BiomarkersLab test / biomarkerriskpartially modifiable
13
evidence score
PREVENT status
Not a PREVENT input variable.
Causal support
trial evidence
Score components
lit volume: 6meta-analyses: 0trials: 7genetic: 0MR bonus:
References (3)
0 meta-analyses / systematic reviews- Homocysteine-Induced Endothelial Dysfunction — Annals of Nutrition and Metabolism 2015 · PMID 26201664
- Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease — Circulation Research 2005 · PMID 16100045
- ADMA and hyperhomocysteinemia. — Vascular medicine (London, England) 2005 · PMID 16444866
Clinical trials (4)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT05703126 | Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With Acute Myeloid Leukemia | RECRUITING | INTERVENTIONAL | History taking, Anthropometry, Complete blood count |
| NCT03377465 | Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis | COMPLETED | INTERVENTIONAL | ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin |
| NCT02022046 | Methylation Biosignature in Childhood Chronic Kidney Disease: the Link Among Asymmetric Dimethylarginine, Homocysteine, and Cardiovascular Disease | COMPLETED | OBSERVATIONAL | Methylation biosignature |
| NCT00161369 | Contribution of Homocysteine and Asymmetric Dimethylarginine to Atherosclerosis and Cardiovascular Events in Maintenance Hemodialysis Patients | COMPLETED | OBSERVATIONAL |
Genetic associations (0)
None linked.